L-Valine
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | L-Valine |
|---|---|
| Chemical class | Essential branched-chain α-amino acid — isopropyl side chain, hydrophobic |
| CAS | 72-18-4 |
| Primary source | Microbial fermentation, typically Corynebacterium glutamicum |
| Key applications | BCAA blends, muscle protein substrate, nitrogen transport, gluconeogenic precursor |
| Claim strength | High for essentiality; low for isolated supplementation benefit |
| Typical form | Crystalline powder at 98–99% |
| Buy from Herbuno | L-Valine 98% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: Named for valeric acid, which it resembles structurally — valeric acid itself takes its name from valerian, Valeriana officinalis, from whose root it was first obtained. Emil Fischer isolated valine in 1901. It is one of the three branched-chain amino acids, sharing the branched aliphatic side chain with leucine and isoleucine.
Discovery and production history: Valine is essential because humans lack the enzymatic machinery to construct its branched carbon skeleton. It is also, unusually among amino acids, purely glucogenic — its carbon skeleton feeds into succinyl-CoA and can be converted to glucose, where leucine is purely ketogenic and isoleucine is both. This metabolic difference is why the three behave differently in fasting and catabolic states despite being grouped together. Industrial production moved to fermentation in the mid-twentieth century alongside the other commodity amino acids.
Research trajectory: Valine has comparatively little independent research literature, because it is almost always studied as part of a BCAA combination rather than alone. Its most significant standalone clinical context is maple syrup urine disease, an inherited defect in branched-chain ketoacid dehydrogenase where valine, leucine and isoleucine accumulate to neurotoxic concentrations and dietary restriction is the treatment. A smaller literature examines valine in hepatic encephalopathy as part of BCAA therapy.
Commercial source: L-valine is produced by fermentation using Corynebacterium glutamicum or related organisms on a carbohydrate substrate, then crystallised to 98% or above. The scale is driven largely by animal feed demand, as with lysine and threonine, with supplement-grade material representing a smaller and more tightly specified fraction of the same industry. Substrate determines vegan, non-GMO, kosher and halal eligibility.
Evidence for L-Valine Applications
Valine has no meaningful standalone supplementation evidence, and that should be the starting point rather than an omission. It is almost never studied alone; where it appears in trials it is as one component of a BCAA or essential amino acid mixture, and those designs cannot isolate its contribution. There is no body of work showing that supplementing valine specifically improves performance, recovery, body composition or any other endpoint in people eating adequate protein. Its commercial existence rests on being one third of a conventional ratio. Claim strength: Emerging, and effectively absent.
The 2:1:1 ratio is convention, not a dose-ranging result. Leucine, isoleucine and valine are conventionally blended two parts to one to one, a ratio that approximates their relative abundance in muscle protein and in whey. It has not been established by comparative trials testing alternative ratios against outcomes. Products marketing 4:1:1, 8:1:1 or 10:1:1 as superior are making claims the literature does not support either, since the comparative work simply has not been done. The honest statement is that the ratio is a reasonable default with no trial behind it. Claim strength: High for the absence of evidence either way.
Valine is purely glucogenic, which distinguishes it metabolically from leucine and matters in specific contexts. Its carbon skeleton is catabolised to succinyl-CoA and can enter gluconeogenesis, so valine can contribute to glucose production during fasting or prolonged exercise, where leucine cannot. This is a real metabolic distinction rather than a marketing one, though it has not translated into a demonstrated performance application. In clinical nutrition it is part of why BCAA mixtures behave differently from leucine alone in catabolic states. Claim strength: High for the biochemistry.
The BCAA transport competition applies to valine as it does to the group, and is worth carrying into formulation decisions. Branched-chain amino acids compete with aromatic amino acids — tryptophan, tyrosine, phenylalanine — for the large neutral amino acid transporter at the blood-brain barrier. High BCAA intake therefore reduces central tryptophan availability and serotonin synthesis. This underlies BCAA use in hepatic encephalopathy and is a reason to think carefully before combining high-dose BCAAs with products positioned for mood, sleep or relaxation. Claim strength: Moderate.
Maple syrup urine disease is the one context where valine concentration is clinically critical, and it runs opposite to supplementation. This inherited deficiency of branched-chain ketoacid dehydrogenase causes valine, leucine and isoleucine and their ketoacids to accumulate to neurotoxic levels, producing the characteristic sweet-smelling urine that names the condition. Management is lifelong dietary restriction of all three. Any high-BCAA product is contraindicated, and while the condition is rare, it is a genuine contraindication rather than a theoretical one. Claim strength: High.
Safety at supplemental doses is good with the usual caveat about limited characterisation. Valine within BCAA blends at conventional doses is well tolerated. No tolerable upper intake level has been established, which reflects absence of systematic assessment rather than demonstrated safety at any level. Very high isolated intake of a single branched-chain amino acid can in principle create an imbalance that impairs uptake of the other two through transporter competition, which is an argument for blended rather than isolated use. Claim strength: Moderate.
Sourcing L-valine from Herbuno. We supply fermentation-derived L-valine at 98% as a crystalline powder, suitable for BCAA and EAA blends, clinical nutrition and powder formats.
Most enquiries are for blend inclusion rather than standalone use, which matches where the evidence sits. All lots ship with CoA and MSDS as standard; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
Valine is dosed as the free amino acid at 98% or above, so declared weight is close to delivered weight. In a conventional 2:1:1 BCAA blend, valine occupies one quarter of the total: a 5 gram BCAA serving delivers 1.25 grams of valine alongside 2.5 grams of leucine. Adult requirement is around 26 milligrams per kilogram daily, readily met by adequate protein intake. There is no established standalone supplemental dose, because there is no standalone application the evidence supports.
If the formulation objective is muscle protein synthesis, the same argument applies here as to leucine: a complete essential amino acid profile outperforms BCAAs, because synthesis is limited by the full substrate set rather than by the branched-chains alone. Valine's role in a rational formulation is therefore as one of nine essentials dosed against a target profile, not as a headline ingredient. Where a BCAA product is required for market reasons, 2:1:1 is the defensible default precisely because no ratio has been shown superior.
Solubility is moderate and better than leucine, which affects blend design. Valine dissolves at around 8.5 grams per 100 millilitres at room temperature, considerably more readily than leucine's 2.4, so in a BCAA blend leucine is the component that determines whether the mixture disperses acceptably. Valine is distinctly bitter, as the branched-chains generally are, and the bitterness compounds across the blend. Glycine in the formula helps, and instantised grades of the poorly-dispersing components are usually necessary for ready-to-mix formats.
For analytical control, specify identity and assay by HPLC or ion-exchange chromatography with optical rotation confirming L-configuration, since D- and DL- material is cheaper and nutritionally inert. Standard amino acid specifications cover heavy metals, residual solvents, microbiological limits and loss on drying, and the certificate should name the fermentation organism and substrate for vegan, non-GMO, kosher and halal documentation. Valine is fermentation-derived rather than plant-extracted, so phytosanitary certification does not apply; CoA and MSDS ship as standard.
Two points on supplier qualification deserve attention in this category specifically. First, the branched-chain amino acid market is dominated by feed-grade volume, and the specification gap between feed and supplement grade is real rather than nominal — microbiological limits, residual host-cell protein from the fermentation organism, endotoxin and heavy metals are all controlled more tightly for human-grade material, and a price substantially below the prevailing supplement-grade range is worth interrogating rather than celebrating. Second, instantised grades carry a lecithin or similar wetting agent that must be declared and that affects allergen labelling: soy lecithin in an instantised BCAA blend is a soy declaration, which matters for a product otherwise positioned as allergen-free. Confirm both the presence and the source of any instantising agent at the specification stage rather than discovering it from a finished-goods label review.
For blend construction, the practical sequence is to fix the leucine inclusion first, since leucine determines both the dispersion behaviour and the bulk of the cost, then calculate valine and isoleucine against the chosen ratio, then add the masking and flow system. Working in that order avoids the common outcome of a blend that meets its label ratio but will not wet out or that requires so much masking agent that the active loading falls below the target serving size. Where the finished format is a capsule rather than a powder, the solubility and bitterness constraints largely disappear, but the bulk density of the three crystalline powders then becomes the limiting factor on how much active fits a given capsule size — worth calculating before committing to a serving architecture.
Frequently Asked Questions — L-Valine
Is there evidence for supplementing valine on its own?
No meaningful body of it. Valine is almost never studied alone — it appears in trials as one component of BCAA or EAA mixtures, and those designs cannot isolate its contribution. There is no work showing standalone valine improves performance, recovery or body composition in people eating adequate protein. Its commercial existence rests on being part of a ratio.
Is 2:1:1 the right BCAA ratio?
It is a reasonable default with no trial behind it. The ratio approximates the relative abundance of the three in muscle protein and in whey, but it has not been established by comparative dose-ranging. Equally, products claiming 8:1:1 or 10:1:1 is superior are not supported either — the comparative work simply has not been done.
How is valine different from leucine metabolically?
Valine is purely glucogenic: its carbon skeleton goes to succinyl-CoA and can be converted to glucose. Leucine is purely ketogenic and cannot. Isoleucine is both. That is a real distinction behind why BCAA mixtures behave differently from leucine alone in fasting and catabolic states, though it has not translated into a demonstrated performance application.
Who should avoid BCAA products?
Anyone with maple syrup urine disease. It is an inherited deficiency of branched-chain ketoacid dehydrogenase in which valine, leucine and isoleucine accumulate to neurotoxic levels, and management is lifelong restriction of all three. Rare, but a genuine contraindication rather than a theoretical one.
Which BCAA causes the mixing problem?
Leucine. Valine dissolves at around 8.5 g per 100 ml, leucine at about 2.4, so leucine determines whether a blend disperses acceptably. All three are bitter and the bitterness compounds. Instantised leucine and glycine in the formula are the usual answers for ready-to-mix.
Why source valine from India?
Around 80% of raw nutraceutical ingredients originate in China and amino acids are among the most concentrated categories, so a qualified second origin is a continuity measure. India has established fermentation capacity with the certification infrastructure for vegan, non-GMO, kosher and halal documentation.